Padlock Therapeutics

Padlock Therapeutics is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock is based in Cambridge, MA.

Latest News Entry
Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego

Padlock Therapeutics, a biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, today announced the appointment of Kerri Mowen, Ph.D., one of

Padlock Therapeutics - An unconventional approach to autoimmunity

Doctors have long treated autoimmune diseases such as arthritis and lupus as a case of a confused immune system: Immune cells decide healthy tissue looks foreign and wage an attack.

Padlock Therapeutics Appoints Adelene Perkins to Board of Directors

Veteran deal-maker and company-builder provides extensive corporate leadership and operational experience as Padlock expands its team and advances multiple programs

Padlock Therapeutics Named by FierceBiotech as a 2015 “Fierce15” Biotech Company

Padlock Therapeutics Named by FierceBiotech as a 2015 “Fierce15” Biotech Company

Padlock Therapeutics Accelerates Pipeline Development Through Agreement with GSK

Creates Industry - Leading R&D Effort Focused on Creating PAD Inhibitors for the Treatment of Autoimmune Diseases ...

Padlock Therapeutics Assembles Scientific Advisory Board with World Leaders in PAD Enzyme Biology and Autoimmune Disease

Company strengthens its position as a leader in developing new treatments for autoimmune disease focus ed on protein citrullination ...

Padlock Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of PAD Enzymes

Institutions to Conduct Disease - Specific Pre-clinical Studies With the Company’s Proprietary Investigational Compounds ...

Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration

Evotec AG and Padlock Therapeutics, Inc. (“Padlock”) announced today that they have successfully completed an initial goal ...

all related news
all portfolio news